The effect of anticholinergic drugs on cognition of patients with Parkinson’s disease: a cohort study from the Egyptian population

References

• de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–535. doi: 10.1016/S1474-4422(06)70471-9
   PubMed Web of Science ®Google Scholar
• Pfeiffer HC, Løkkegaard A, Zoetmulder M, et al. Cognitive impairment in early-stage non-demented Parkinson’s disease patients. Acta Neurol Scand. 2014;129(5):307–318. doi: 10.1111/ane.12189
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844. doi: 10.1002/mds.21956
   PubMed Web of Science ®Google Scholar
• Aarsland D, Kurz MW. The epidemiology of dementia associated with parkinson disease. J Neurol Sci. 2010;289(1–2):18–22. doi: 10.1016/j.jns.2009.08.034
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–1707. doi: 10.1002/mds.21507
   PubMed Web of Science ®Google Scholar
• Pagonabarraga J, Kulisevsky J. Cognitive impairment and dementia in Parkinson’s disease. Neurobiol Dis. 2012;46(3):590–596. doi: 10.1016/j.nbd.2012.03.029
   PubMed Web of Science ®Google Scholar
• Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9(12):1200–1213. doi: 10.1016/S1474-4422(10)70212-X
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–392. doi: 10.1001/archneur.60.3.387
   PubMedGoogle Scholar
• Albin RL, van der Zee S, van Laar T, et al. Cholinergic systems, attentional-motor integration, and cognitive control in Parkinson’s disease. Prog Brain Res. 2022;269(1):345–371.
   PubMedGoogle Scholar
• Narayanan NS, Albin RL. The way forward for cognition in Parkinson’s disease. Prog Brain Res. 2022;269(1):457–462.
   PubMedGoogle Scholar
• Zhang Q, Aldridge GM, Narayanan NS, et al. Approach to cognitive impairment in Parkinson’s disease. Neurotherapeutics. 2020;17(4):1495–1510. doi: 10.1007/s13311-020-00963-x
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of parkinson disease: a review. JAMA. 2014;311(16):1670–1683. doi: 10.1001/jama.2014.3654
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. Movement disorder society evidence-based medicine committee. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–1266. doi: 10.1002/mds.27372
   PubMed Web of Science ®Google Scholar
• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601. doi: 10.1002/mds.26424
   PubMed Web of Science ®Google Scholar
• El-Gilany A, El-Wehady A, El-Wasify M. Updating and validation of the socioeconomic status scale for health research in Egypt. East Mediterr Health J. 2012;18(9):962–968. doi: 10.26719/2012.18.9.962
   PubMedGoogle Scholar
• Goetz CG, Poewe W, Rascol O, et al. Movement disorder society task force on rating scales for Parkinson’s disease. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020–1028. doi: 10.1002/mds.20213
   PubMed Web of Science ®Google Scholar
• Abdel-Khalek AM. Internal consistency of an arabic adaptation of the beck depression inventory in four Arab countries. Psychol Rep. 1998;82(1):264–166. doi: 10.2466/pr0.1998.82.1.264
   PubMed Web of Science ®Google Scholar
• El-Hayeck R, Baddoura R, Wehbé A, et al. An Arabic version of the mini-mental state examination for the Lebanese population: reliability, validity, and normative data. J Alzheimers Dis. 2019;71(2):525–540. doi: 10.3233/JAD-181232
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bédirian V, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–659. doi: 10.1111/j.1532-5415.2005.53221.x
   PubMed Web of Science ®Google Scholar
• Benito-León J, Louis ED, Posada IJ, et al. Population-based case-control study of cognitive function in early Parkinson’s disease (NEDICES). J Neurol Sci. 2011;310(1–2):176–182. doi: 10.1016/j.jns.2011.06.054
   PubMed Web of Science ®Google Scholar
• Lessig S, Nie D, Xu R, et al. Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord. 2012;27(9):1125–1128. doi: 10.1002/mds.25070
   PubMed Web of Science ®Google Scholar
• Burté F, Houghton D, Lowes H, et al. Metabolic profiling of Parkinson’s disease and mild cognitive impairment. Mov Disord. 2017;32(6):927–932. doi: 10.1002/mds.26992
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255–1263. doi: 10.1002/mds.20527
   PubMed Web of Science ®Google Scholar
• Saredakis D, Collins-Praino LE, Gutteridge DS, et al. Conversion to MCI and dementia in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2019;65:20–31. doi: 10.1016/j.parkreldis.2019.04.020
   PubMed Web of Science ®Google Scholar
• Cameron IG, Watanabe M, Pari G, et al. Executive impairment in Parkinson’s disease: response automaticity and task switching. Neuropsychologia. 2010;48(7):1948–1957. doi: 10.1016/j.neuropsychologia.2010.03.015
   PubMed Web of Science ®Google Scholar
• Sollinger AB, Goldstein FC, Lah JJ, et al. Mild cognitive impairment in Parkinson’s disease: subtypes and motor characteristics. Parkinsonism Relat Disord. 2010;16(3):177–180. doi: 10.1016/j.parkreldis.2009.11.002
   PubMed Web of Science ®Google Scholar
• Allain H, Lieury A, Quemener V, et al. Procedural memory and Parkinson’s disease. Dementia. 1995;6(3):174–178. doi: 10.1159/000106942
   PubMedGoogle Scholar
• Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated Parkinson’s disease and its relationship to motor disability. Brain. 1991;114(Pt 5):2095–2122. doi: 10.1093/brain/114.5.2095
   PubMedGoogle Scholar
• Sullivan EV, Sagar HJ. Double dissociation of short-term and long-term memory for nonverbal material in Parkinson’s disease and global amnesia. A further analysis. Brain. 1991;114(Pt 2):893–906. doi: 10.1093/brain/114.2.893
   PubMedGoogle Scholar
• Boller F, Passafiume D, Keefe NC, et al. Visuospatial impairment in Parkinson’s disease. Role of perceptual and motor factors. Arch Neurol. 1984;41(5):485–490. doi: 10.1001/archneur.1984.04050170031011
   PubMedGoogle Scholar
• Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253(2):242–247. doi: 10.1007/s00415-005-0971-0
   PubMed Web of Science ®Google Scholar
• Mattila PM, Röyttä M, Lönnberg P, et al. Choline acetytransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol. 2001;102(2):160–166. doi: 10.1007/s004010100372
   PubMed Web of Science ®Google Scholar
• Pasquini J, Brooks DJ, Pavese N. The cholinergic brain in Parkinson’s disease. Mov Disord Clin Pract. 2021;8(7):1012–1026. doi: 10.1002/mdc3.13319
   PubMed Web of Science ®Google Scholar
• Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005 13;65(11):1716–1722. doi: 10.1212/01.wnl.0000191154.78131.f6
   PubMed Web of Science ®Google Scholar
• Nobili F, Arnaldi D, Campus C, et al. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38(12):2209–2218. doi: 10.1007/s00259-011-1874-1
   PubMed Web of Science ®Google Scholar
• Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson’s disease dementia. Brain Pathol. 2010;20(3):646–653. doi: 10.1111/j.1750-3639.2009.00368.x
   PubMed Web of Science ®Google Scholar
• Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40(3):399–410. doi: 10.1002/ana.410400309
   PubMed Web of Science ®Google Scholar
• Fahn S. The medical treatment of parkinson disease from James parkinson to George Cotzias. Mov Disord. 2015;30(1):4–18. doi: 10.1002/mds.26102
   PubMed Web of Science ®Google Scholar
• Scharre DW, Mahler ME. Parkinson’s disease: making the diagnosis, selecting drug therapies. Geriatrics. 1994;49(10):14–16, 20–3.
   Web of Science ®Google Scholar
• Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003;2002(2):CD003735. doi: 10.1002/14651858.CD003735
   PubMedGoogle Scholar
• Pisani A, Bernardi G, Ding J, et al. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 2007;30(10):545–553. doi: 10.1016/j.tins.2007.07.008
   PubMed Web of Science ®Google Scholar
• Betz AJ, McLaughlin PJ, Burgos M, et al. The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors. Psychopharmacology. 2007;194(3):347–359. doi: 10.1007/s00213-007-0844-6
   PubMed Web of Science ®Google Scholar
• Moehle MS, Conn PJ. Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders. Mov Disord. 2019;34(8):1089–1099. doi: 10.1002/mds.27740
   PubMed Web of Science ®Google Scholar
• Arany S, Kopycka-Kedzierawski DT, Caprio TV, et al. Anticholinergic medication: related dry mouth and effects on the salivary glands. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;132(6):662–670. doi: 10.1016/j.oooo.2021.08.015
   PubMed Web of Science ®Google Scholar
• Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003;2003(1):CD003468. doi: 10.1002/14651858.CD003468
   PubMedGoogle Scholar
• Paquette MA, Martinez AA, Macheda T, et al. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson’s disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci. 2012;36(9):3224–3234. doi: 10.1111/j.1460-9568.2012.08243.x
   PubMed Web of Science ®Google Scholar
• Dubois B, Pilon B, Lhermitte F, et al. Cholinergic deficiency and frontal dysfunction in Parkinson’s disease. Ann Neurol. 1990;28(2):117–121. doi: 10.1002/ana.410280202
   PubMed Web of Science ®Google Scholar
• Bédard MA, Pillon B, Dubois B, et al. Acute and long-term administration of anticholinergics in Parkinson’s disease: specific effects on the subcortico-frontal syndrome. Brain Cogn. 1999;40(2):289–313. doi: 10.1006/brcg.1999.1083
   PubMed Web of Science ®Google Scholar
• Syndulko K, Gilden ER, Hansch EC, et al. Decreased verbal memory associated with anticholinergic treatment in Parkinson’s disease patients. Int J Neurosci. 1981;14(1–2):61–66. doi: 10.3109/00207458108985816
   PubMed Web of Science ®Google Scholar
• Nishiyama K, Sugishita M, Kurisaki H, et al. Reversible memory disturbance and intelligence impairment induced by long-term anticholinergic therapy. Intern Med. 1998;37(6):514–518. doi: 10.2169/internalmedicine.37.514
   PubMed Web of Science ®Google Scholar
• Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain. 1992;115(Pt 6):1701–1725. doi: 10.1093/brain/115.6.1701
   PubMedGoogle Scholar
• Pondal M, Del Ser T, Bermejo F. Anticholinergic therapy and dementia in patients with Parkinson’s disease. J Neurol. 1996;243(7):543–546. doi: 10.1007/BF00886877
   PubMed Web of Science ®Google Scholar
• Ehrt U, Broich K, Larsen JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81(2):160–165. doi: 10.1136/jnnp.2009.186239
   PubMed Web of Science ®Google Scholar
• Barrett MI, Sargent L, Nawaz H, et al. Antimuscarinic anticholinergic medications in parkinson disease: to prescribe or deprescribe? Mov Disord Clin Pract. 2021;8(8):1181–1188. doi: 10.1002/mdc3.13347
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407. doi: 10.1001/jamainternmed.2014.7663
   PubMed Web of Science ®Google Scholar
• Sheu JJ, Tsai MT, Erickson SR, et al. Association between anticholinergic medication use and risk of dementia among patients with Parkinson’s disease. Pharmacotherapy. 2019;39(8):798–808. doi: 10.1002/phar.2305
   PubMed Web of Science ®Google Scholar
• Meng D, Mohammadi‐Nejad A, Sotiropoulos SN, et al. The Alzheimer’s disease neuroimaging initiative. Anticholinergic drugs and forebrain magnetic resonance imaging changes in cognitively normal people and those with mild cognitive impairment. Eur J Neurol. 2022;29(5):1344–1353. doi: 10.1111/ene.15251
   PubMedGoogle Scholar
• Weintraub D, Simuni T, Caspell-Garcia C, et al. Parkinson’s progression markers initiative. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord. 2015;30(7):919–927. doi: 10.1002/mds.26170
   PubMed Web of Science ®Google Scholar
• Dubaz OM, Wu S, Cubillos F, et al. Parkinson’s foundation quality improvement initiative investigators. Changes in prescribing practices of dopaminergic medications in individuals with Parkinson’s disease by expert care centers from 2010 to 2017: The Parkinson’s foundation quality improvement initiative. Mov Disord Clin Pract. 2019;6(8):687–692. doi: 10.1002/mdc3.12837
   PubMed Web of Science ®Google Scholar
• Mann A, Miksys SL, Gaedigk A, et al. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson’s disease patients. Neurobiol Aging. 2012;33(9):2160–2171. doi: 10.1016/j.neurobiolaging.2011.08.014
   PubMed Web of Science ®Google Scholar
• Risacher SL, McDonald BC, Tallman EF, et al. Alzheimer’s disease neuroimaging initiative. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721–732. doi: 10.1001/jamaneurol.2016.0580
   PubMed Web of Science ®Google Scholar
• López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L. Anticholinergic drugs in geriatric psychopharmacology. Front Neurosci. 2019;13:1309. doi: 10.3389/fnins.2019.01309
   PubMed Web of Science ®Google Scholar
• van Herwaarden G, Berger HJ, Horstink MW. Short-term memory in Parkinson’s disease after withdrawal of long-term anticholinergic therapy. Clin Neuropharmacol. 1993;16(5):438–443. doi: 10.1097/00002826-199310000-00006
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2
   PubMedGoogle Scholar
• Dubois B, Tolosa E, Katzenschlager R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230–1238. doi: 10.1002/mds.25098
   PubMed Web of Science ®Google Scholar
• Mantri S, Fullard M, Gray SL, et al. Patterns of dementia treatment and frank prescribing errors in older adults with parkinson disease. JAMA Neurol. 2019;76(1):41–49. doi: 10.1001/jamaneurol.2018.2820
   PubMed Web of Science ®Google Scholar
• Song IU, Kim JS, Ryu SY, et al. Donepezil-induced jaw tremor. Parkinsonism Relat Disord. 2008;14(7):584–585. doi: 10.1016/j.parkreldis.2008.01.003
   PubMed Web of Science ®Google Scholar
• Collins LE, Paul NE, Abbas SF, et al. Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer’s disease. Pharmacol Biochem Behav. 2011;99(3):414–422. doi: 10.1016/j.pbb.2011.05.026
   PubMed Web of Science ®Google Scholar
• Alzahrani H, Venneri A. Cognitive rehabilitation in Parkinson’s disease: a systematic review. J Parkinsons Dis. 2018;8(2):233–245. doi: 10.3233/JPD-171250
   PubMedGoogle Scholar
• Machado-Alba JE, Calvo-Torres LF, Gaviria-Mendoza A, et al. Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015. Biomedica. 2018;38(3):417–426. doi: 10.7705/biomedica.v38i4.3781
   PubMed Web of Science ®Google Scholar